STAG3 cohesin complex component like 1 (pseudogene)Genealiases: []
Q-omics provides the consensus-scored STAG3L1 profile across patient tissues and cancer cell-line models. STAG3L1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STAG3L1 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, STAG3L1 RNA expression shows 18,645 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where STAG3L1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STAG3L1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STAG3L1 survival associations across molecular data types. STAG3L1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STAG3L1 RNA expression–survival associations across cancer types. High STAG3L1 expression shows unfavorable associations in KIRC, but favorable associations in STAD, LUAD, PAAD, UCS and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for STAG3L1 RNA expression.
This table summarizes STAG3L1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for STAG3L1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STAG3L1 shows lower tumor expression in BRCA and higher tumor expression in HNSC, STAD, COAD, LIHC and READ. The HNSC box plot shows higher STAG3L1 RNA expression in tumor versus normal tissue (log2 FC = +0.245, t-test p = .001).
This table shows molecular features associated with STAG3L1 in patient tissues and cancer cell lines. In patient samples, STAG3L1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
